Italian Strategic Fund invests in Kedrion
Fondo Strategico Italiano (FSI), the Italian Strategic Fund, has become a joint owner of Kedrion with an overall financial contribution of 150 million euros (75 million euros in capital increase and 75 million euros in a convertible or reimbursable line of credit). The company’s ownership will be divided as follows: 48.8 per cent to the
Kedrion supports the World Haemophilia Day
Kedrion confirms its commitment to improving access to treatment and protecting the therapeutic standards of people suffering from haemophilia and other haemorrhagic conditions. The company is actually one of the supporters of the initiatives implemented in Rome by FedEmo (Federation of haemophilic patients’ associations) and in Milan by Fondazione Paracelso to celebrate the eighth World
Kedrion CEO assumes board helm of Plasma Protein Therapeutics Association
At the yearly PPTA meeting in Brussels, Paolo Marcucci has been elected as new chairman of the Global Board of Directors of the Plasma Protein Therapeutics Association. Paolo Marcucci has served on the PPTA Global Board of Directors since 2008. “It will be a great honor and privilege to serve as the new chairman of
The Regional Health Councillor for Tuscany Daniela Scaramuccia visits Kedrion’s plant in Bolognana (Lucca, Italy)
The Regional Health Councillor for Tuscany, Daniela Scaramuccia, visited Kedrion’s plant in Bolognana (Lucca, Italy), with Simona Carli, Regional Director of the National Blood Centre of Tuscany. They were received by Paolo Marcucci, President and CEO of Kedrion, along with the company’s management. It was a particularly important visit for Kedrion, since it was the
Kedrions wins the “Transatlantic Award 2011” of the American Chamber of Commerce in Italy
Last night, the President of the American Chamber of Commerce in Italy, Vittorio Terzi, gave Paolo Marcucci, President and CEO of Kedrion, the “Transatlantic Award 2011” for the company’s response to the challenges of the international market by investing in quality and technological innovation and for its success in the US market. In 2011, Kedrion
Rare diseases: Kedrion hoping for temporary authorisation for use of drugs (ATU) in Italy
«It is essential to insist on how important the ATU, i.e. Autorizzazione Temporanea di Utilizzo or Temporary Authorisation for use of orphan or life saving drugs, is for patients, so that quick access is given to such class of drugs while guaranteeing the products’ safety». This was stated by Rodolfo de Dominicis, Deputy President of
Biological Safetry Centre BIOSC, the innovation selected by “Italia degli Innovatori”
The Biological Safety Centre BioSC will take part in the “Italia degli Innovatori 2011/2012” project, an initiative promoted by the Italian Government to showcase an Italy that can do innovation and our country’s excellent technological achievements. BioSC, a centre specialising in viral validation studies which has been working at the Kedrion’s plant in Bolognana (Lucca
Kedrion receives FDA authorisation to sell its Albumin on the US market
Kedrion announces that on 3rd June 2011 it has received from the Food and Drug Administration, the government agency responsible for supervising and authorising the marketing of pharmaceuticals in the United States, the authorisation to sell its albumin on the US market, with the brand name KEDBUMIN. Under such authorisation, Kedrion will produce albumin for
Kedrion reinforces its presence in the US. Closed acquisition of Grifols’ assets. Incorporation of the new Kedrion Biopharma
Kedrion, a biopharmaceutical company specialising in the development, production and distribution of plasma-derived medicinal products, announces that, having received the approval from the US Federal Trade Commission (FTC), it has finalized the transaction previously announced on May 2nd relative to the purchase of certain assets from Grifols S.A. and the commercial and manufacturing agreement between
Agreements between Kedrion and Grifols
Kedrion announces today to have reached an agreement with Grifols S.A. (Grifols) for the sale of Grifols’ assets to Kedrion; the two companies also have established commercial, lease and manufacturing agreements for up to seven (7) years. This agreement has been reached in order to satisfy the conditions for the merger transaction between Grifols and